

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 4

**Complete if Known**

Application Number	
Filing Date	Oct. 03, 2003
First Named Inventor	Bobrowski, Paul J.
Art Unit	1654
Examiner Name	Tate
Attorney Docket Number	PHMC0745-023

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
[Signature]		US- 5,837,238	11/17/1998	Casas et al.	
		US- 5489440	02/06/1996	Ndife et al.	
		US- 5038396	08/06/1991	Gjerlov	
		US- 4942042	07/17/1990	Bhargava et al.	
		US- 4704269	11/03/1987	Korab	
		US- 4332814	06/01/1982	Newsome et al.	
		US- 4844901	07/04/1989	Keplinger et al.	
		US- 4940725	07/10/1990	Keplinger et al.	
		US- 5302611	04/12/1994	Keplinger et al.	
		US- 5723625	03/03/1998	Keplinger et al.	
		US- 63039949	03/21/2000	Pero	
		US- 6238675B1	05/29/2001	Pero	
		US- 6361805B2	03/26/2002	Pero	
		US- 5156847	10/20/1992	Lewis et al.	
		US- 5211944	05/18/1993	Tempesta	
[Signature]		US- 5474782	12/12/1995	Winter et al.	
		US- 5494661	02/27/1996	Tempesta	
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

Examiner  
Signature

C. R. Tate

Date  
Considered

4/21/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>			
		<b>Filing Date</b>		Oct. 03, 2003	
		<b>First Named Inventor</b>		Bobrowski, Paul J.	
		<b>Art Unit</b>		1654	
		<b>Examiner Name</b>		Tate	
<b>Sheet</b>	2	<b>of</b>	4	<b>Attorney Docket Number</b>	PHMC0745-023

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		J. Piscoya et al, Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis, Inflamm. res. 50 (2001)	
		MJS Miller et al, Dietary antioxidants protect gut epithelial cells from oxidant-induced apoptosis, BMC Complementary and Alternative Medicine 2001, 1:11, U.S.	
		MJS Miller et al, Inhibition of Neurogenic Inflammation by the Amazonian Herbal Medicine Sangre de Grado, J Invest Dermatol 117:725-730, 2001, U.S.	
		MJS Miller et al, Treatment of gastric ulcers and diarrhea with the Amazonian herbal medicine sangre de grado, Am J Physiol Gastrointest Liver Physiol, 279: G192-G200, 2000 U.S.	
		S. Lamm et al, Persistent response to pneumococcal vaccine in individuals supplemented with a novel water soluble extract of Uncaria ..., C-Med-100®, Phytomedicine, Vol. 8(4), U.S.	
		R Marini et al., Alkaloids of Croton Draconoides, Phytochemistry 1979, Vol. 18, p. 533 UK	
		G Persinos et al, South American Plants II: Taspine Isolation and Anti-Inflammatory Activity, J Pharmaceutical Sciences, Vol 68 No 1, Jan 1979 U.S.	
		A J Vaisberg et al., Taspine is the Cicatrizant Principle in Sangre de Grado Extracted from Croton Lechleri. Planta Medica 55 (1989) U.S.	
		L Peters et al., Isolation of a dihydrobenzofuran Ligan from South American Dragon's Blood (Croton spp.) as an inhibitor of cell proliferation, June 1993 Belgium	
		J D Phillipson, A matter of some sensitivity, Phytochemistry V 38, No 6, pp 1319-1343 1995 UK	

<b>Examiner Signature</b>	C. R. Tate	<b>Date Considered</b>	4/21/05
---------------------------	------------	------------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: C. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet	3	of	4	Application Number	
				Filing Date	Oct. 03, 2003
				First Named Inventor	Bobrowski, Paul J.
				Art Unit	1654
				Examiner Name	Tate
				Attorney Docket Number	PHMC0745-023

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MJS Miller et al, Inhibition of Neurogenic Inflammation by the Amazonian Herbal Medicine Sangre de Grado, J Invest Dermatol 117:725-730, 2001 U.S.	
		SE Gabriel et al, A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion, Am J Physiol 276 : G58-G63, 1999, U.S.	
		M Holodniy et al, A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS, Am J Gastroenterology, V 94 No 11, 1999 U.S.	
		B Illek et al, A novel extract from the bark latex of Croton lechleri inhibits cAMP-mediated chloride secretion in human colonic epithelial cells, Dec. 2000	
		M Sandoval et al, Sangre de Grado Croton palanostigma induces apoptosis in human gastrointestinal cancer cells, J Ethnopharmacology, 80 (2002)	
		Zheng-Ping Chen et al, Studies on the anti-tumour, anti-bacterial, and wound-healing properties of dragon's blood, Planta Med 60 (1994) 541-545, U.S.	
		MJS Miller, Dietary antioxidants protect gut epithelial cells from oxidant-induced apoptosis, BMC Complementary and Alternative Medicine 2001, 1:11, Dec. 2001	
		M Sandoval, Anti-inflammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content, Phytomedicine 9:325-337, 2002	
		M Sandoval et al, Cat's claw inhibits TNF $\alpha$ production and scavenges free radicals: role in cytoprotection, Free Radical Biology & Medicine, V 29, No 1, pp 71-78, 2000. U.S.	
		R Cerri et al., New Quinovic Acid Glycosides from <i>Uncaria tomentosa</i> , J Natural Products, V 51, No 2, pp 257-261, 1988, IT	

Examiner Signature	C. R. Tate	Date Considered	4/21/05
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission r for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet

24

of

24

Application Number

Filing Date

Oct. 03, 2003

First Named Inventor

Bobrowski, Paul J.

Art Unit

1654

Examiner Name

Tate

Attorney Docket Number

PHMC0745-023

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JA		H Stuppner et al, Capillary electrophoretic analysis of oxidole alkaloids from <i>Uncaria tomentosa</i> , J Chromatography, 609 (1992) 375-380, Amsterdam	
		H Stuppner et al, HPLC analysis of the main oxidole alkaloids from <i>Uncaria tomentosa</i> , Chromatographia V 34, no 11/12, Dec 1992,	
		G Laus et al, Separation of stereoisomeric oxidole alkaloids from <i>Uncaria tomentosa</i> by high performance liquid chromatography, J Chromatography A, 662 (1994) 243-249, Austria	
		Y Sheng et al, Induction of Apoptosis and Inhibition of Proliferation in Human Tumor Cells Treated with Extracts of <i>Uncaria Tomentosa</i> , Anticancer Research 18:3363-3368 (1998)	
		M Sandoval-Chacon et al, Antiinflammatory actions of cat's claw: the role of NF-κB, Aliment Pharmacol Ther 1998; 12: 1279-1289, US	
		K Keplinger, <i>Uncaria tomentosa</i> (Willd.) DC.-Ethnomedicinal use and new pharmacological, toxicological and botanical results, J Ethnopharmacology 64 (1999) 23-24	
JA		Y Sheng et al, Enhanced DNA repair, immune function and reduced toxicity of C-MED-100™, a novel aqueous extract from <i>Uncaria tomentosa</i> , J Ethnopharmacology 69 (2000) 115-126	

Examiner  
Signature

C. R. Tate

Date

Considered

4/21/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. END TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.